21 completed, 5 recruiting, 2 unknown, 1 not yet recruiting. 26 Phase 1, 3 Not applicable, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 19, Recruiting 5, Unknown 2 |
| Not applicable | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Sagittal Abdominal Diameter: new trials by email Literature Review of Sagittal Abdominal Diameter trials Research Report on Sagittal Abdominal Diameter
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of SaCo VLMA for General Anesthesia for Laparoscopic Procedures SaCo VLM or SAD or ET for airway control for laparoscopy - Laparoscopic Surgical Procedures, Airway Control | Not applicable | Not yet recruiting | Medical University of Lodz | 20 | 2026-02-01 | 2026-02-06 |
| A Study to Find a Suitable Dose of Exl-111 for Further Research Exl-111 (SAD), Exl-111 (MAD), Placebo - Allergic Disease | Phase 1 | Recruiting | Excellergy Inc. | 70 | 2026-01-08 | 2026-09-22 |
| Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects CHF6467 Part 1 (SAD), CHF6467 Part 2 (MAD), Placebo - Healthy Volunteers | Phase 1 | Recruiting | Chiesi Farmaceutici S.p.A. | 68 | 2025-09-15 | 2026-09-17 |
| EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers, Part B - Multiple Ascending Dose (MAD) in participants with axSpA, Part C - Safety expansion cohort in participants with axSpA - Axial Spondyloarthritis (AxSpA) | Phase 1 / Phase 2 | Recruiting | Grey Wolf Therapeutics | 140 | 2025-07-28 | 2026-09-18 |
| Study of HX15001 in Adult Healthy Volunteers. HX15001 (SAD), Placebo, HX15001 (MAD) - Healthy Volunteers | Phase 1 | Recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 62 | 2025-06-11 | 2025-08-24 |
| Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. Placebo (SAD), RCS-21 (SAD) - Healthy Volunteers, Safety | Phase 1 | Recruiting | RNATICS GmbH | 24 | 2025-02-18 | 2025-11-20 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of G01 Eye Drops in Healthy Volunteers G01 Eye Drops 100 µg/mL SAD, G01 Eye Drops 200 µg/mL SAD, G01 Eye Drops 400 µg/mL SAD - Healhty | Phase 1 | Completed | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 48 | 2024-12-12 | 2026-08-21 |
| A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People DDN-A-0101 (SAD), DDN-A-0101 (MAD), Placebo (SAD) - Alzheimer Disease | Phase 1 | Unknown | Pharmacobio | 100 | 2024-04-01 | 2024-04-16 |
| A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects ENC1018 for SAD, Placebo for SAD, ENC1018 for MAD - Healthy | Phase 1 | Completed | EnnovaBio Australia Pharmaceuticals Pty Ltd | 72 | 2024-03-05 | 2025-04-25 |
| A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients IBI356 for MAD, Dupilumab for MAD, IBI356 for SAD - Healthy Participants, Atopic Dermatitis Patients | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 99 | 2024-01-05 | 2025-09-02 |
| A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects THDBH120 injection (SAD), Placebo of THDBH120 injection (SAD), THDBH120 injection (MAD) - Healthy | Phase 1 | Completed | Tonghua Dongbao Pharmaceutical Co.,Ltd | 72 | 2023-12-19 | 2024-12-27 |
| Waitlist-Control Trial of Smartphone (App-based) CBT for Social Anxiety Disorder (SAD), Withdrawn Smartphone-delivered CBT for SAD - Social Anxiety Disorder | Not applicable | Withdrawn | Massachusetts General Hospital | 2023-09-01 | 2026-07-01 | |
| Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD), immediate-release nicotinic acid (SAD), Placebo controlled-ileal-release nicotinic acid (SAD/MAD) - Safety Issues, Pharmacokinetic | Phase 1 | Completed | University Hospital Schleswig-Holstein | 60 | 2022-12-19 | 2024-11-27 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects SAD, SHR-2004, SAD, SHR-2004 placebo - Prevention of Arterial and Venous Thrombosis | Phase 1 | Unknown | Beijing Suncadia Pharmaceuticals Co., Ltd | 64 | 2022-05-24 | 2022-11-30 |
| Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants IPG1094 300 mg SAD, IPG1094 600 mg SAD, IPG1094 900 mg SAD - Healthy Volunteers | Phase 1 | Completed | Nanjing Immunophage Biotech Co., Ltd | 76 | 2021-09-27 | 2026-05-01 |
| Study of WVE-003 in Patients With Huntington's Disease SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003 - Huntington Disease | Phase 1 / Phase 2 | Completed | Wave Life Sciences USA, Inc. | 47 | 2021-09-06 | 2025-08-12 |
| Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation Trichomylin for SAD, Placebo for SAD, Trichomylin for MAD - Healthy, Osteoarthritis | Phase 1 | Completed | ZYUS Life Sciences Inc. | 41 | 2021-04-19 | 2024-06-27 |
| A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects ACT-777991 (SAD), ACT-777991 (MAD), Placebo (SAD) - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 70 | 2021-01-29 | 2022-06-21 |
| Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM) controlled-ileocolonic-release nicotinamide (SAD/MAD/MD), Immediate-release nicotinamide (SAD), Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD) - Safety Issues, Pharmacokinetic | Phase 1 | Completed | University Hospital Schleswig-Holstein | 49 | 2020-12-04 | 2022-11-08 |
| A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects ACT-1014-6470 (SAD), ACT-1014-6470 (MAD), Placebo (SAD) - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 88 | 2019-11-25 | 2020-08-12 |
Showing 20 of 30. Sign in to see all of them.
Hepatitis (2) · Hepatitis B (2) · Phobia, Social (2) · Alzheimer Disease (1) · Axial Spondyloarthritis (1) · Chronic Pain (1) · Diabetes Mellitus, Type 2 (1) · Huntington Disease (1) · Inflammatory Bowel Diseases (1) · Osteoarthritis (1) · Prediabetic State (1) · Respiratory Aspiration (1) · Seasonal Affective Disorder (1) · Venous Thrombosis (1)
Gilead Sciences (2) · Idorsia Pharmaceuticals Ltd. (2) · University Hospital Schleswig-Holstein (2) · AstraZeneca (1) · Beijing Suncadia Pharmaceuticals Co., Ltd (1) · Chiesi Farmaceutici S.p.A. (1) · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. (1) · EnnovaBio Australia Pharmaceuticals Pty Ltd (1) · Excellergy Inc. (1) · GlaxoSmithKline (1) · Grey Wolf Therapeutics (1) · Helixon Biotechnology (Suzhou) Co., Ltd (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Komazawa University (1) · Kowa Company, Ltd. (1)
Australia (10) · China (6) · Germany (6) · United States (5) · Canada (4) · Netherlands (4) · New Zealand (3) · South Korea (3) · Poland (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Denmark (1) · France (1)
Benedetta Massetto, M.D. (2) · Susanna Nikolaus, Prof. Dr. (2) · Annelize Koch, MBChB (1) · Christopher Argent (1) · In-Jin Jang, Doctor (1) · Kohki Arimitsu, Ph.D. (1) · Maya Dabcheva, MD (1) · Paul Wabnitz, Dr (1) · Philip Ryan, Doctor (1) · Pingsheng Xu, PhD (1) · Rainard Fuhr, Dr. med. (1) · Sabine Wilhelm, PhD (1)
PMID 32161949, PMID 34491803, PMID 36463457, PMID 39027419, PMID 39166425
2016 (1), 2025 (1)